(NASDAQ: BNTX) Biontech Se's forecast annual revenue growth rate of -7.17% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.49%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.23%.
Biontech Se's revenue in 2026 is $3,300,235,294.On average, 25 Wall Street analysts forecast BNTX's revenue for 2026 to be $529,135,622,820, with the lowest BNTX revenue forecast at $476,342,045,940, and the highest BNTX revenue forecast at $579,769,462,464. On average, 23 Wall Street analysts forecast BNTX's revenue for 2027 to be $554,092,586,436, with the lowest BNTX revenue forecast at $339,318,716,856, and the highest BNTX revenue forecast at $754,228,236,972.
In 2028, BNTX is forecast to generate $646,961,287,584 in revenue, with the lowest revenue forecast at $323,240,672,988 and the highest revenue forecast at $785,904,383,100.